Aptose Biosciences (NASDAQ:APTO) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Friday,Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptose Biosciences in a research report on Wednesday. They set a “hold” rating for the company.

Aptose Biosciences Stock Up 3.2 %

APTO stock opened at $0.22 on Friday. The company’s 50-day moving average price is $0.25 and its two-hundred day moving average price is $0.41. The firm has a market cap of $13.24 million, a P/E ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.48.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.